This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
by Indrajit Bandyopadhyay
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
by Zacks Equity Research
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
by Indrajit Bandyopadhyay
Intuitive Surgical's installed base tops 10,000, but flat utilization growth raises questions about ROI and system productivity.
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong
by Harshit Gupta
Intuitive Surgical trims margin outlook on tariff headwinds, but strong procedure growth and financial resilience bolster its long-term case.
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
by Zacks Equity Research
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zimmer Biomet (ZBH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.84% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.
ZBH Stock to Gain From Volume Growth Amid Rising Costs
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
by Sridatri Sarkar
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.
Zimmer Biomet Focuses on Innovation Amid Growing Competition
by Zacks Equity Research
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
by Zacks Equity Research
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
by Zacks Equity Research
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.43% and 0.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Zimmer (ZBH) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.